Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group.

@article{Wiesbeck1999RitanserinIR,
  title={Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group.},
  author={Gerhard Adam Wiesbeck and H Gerd Weijers and Jonathan Chick and Claudio A. Naranjo and Jobst Boening},
  journal={Alcoholism, clinical and experimental research},
  year={1999},
  volume={23 2},
  pages={230-5}
}
Ritanserin, a long-acting specific 5-HT2 receptor antagonist, revealed promising effects on alcohol intake behavior in both animal and preliminary human studies. To test its effectiveness in alcohol dependence this phase III clinical trial was initiated. In a placebo-controlled, randomized, double-blind international multicenter study 493 patients with moderate or severe alcohol dependence (DSM-III-R) were treated with three doses of ritanserin 2.5 mg/day (n = 122), 5 mg/day (n = 123), 10 mg… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Classic hallucinogens in the treatment of addictions

Progress in Neuro-Psychopharmacology and Biological Psychiatry • 2016

Similar Papers

Loading similar papers…